[go: up one dir, main page]

CL2024001452A1 - Formulaciones inyectables e inhalables - Google Patents

Formulaciones inyectables e inhalables

Info

Publication number
CL2024001452A1
CL2024001452A1 CL2024001452A CL2024001452A CL2024001452A1 CL 2024001452 A1 CL2024001452 A1 CL 2024001452A1 CL 2024001452 A CL2024001452 A CL 2024001452A CL 2024001452 A CL2024001452 A CL 2024001452A CL 2024001452 A1 CL2024001452 A1 CL 2024001452A1
Authority
CL
Chile
Prior art keywords
dimethyltryptamine
compound
formulations
optionally substituted
aqueous pharmaceutical
Prior art date
Application number
CL2024001452A
Other languages
English (en)
Spanish (es)
Inventor
Rands Peter
Routledge Carol
Layzell Marie
James Ellen
Joel Zelah
Benway Tiffanie
Good Meghan
Original Assignee
Cybin Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW110143066A external-priority patent/TWI891942B/zh
Priority claimed from GBGB2119021.0A external-priority patent/GB202119021D0/en
Application filed by Cybin Uk Ltd filed Critical Cybin Uk Ltd
Publication of CL2024001452A1 publication Critical patent/CL2024001452A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2024001452A 2021-11-18 2024-05-15 Formulaciones inyectables e inhalables CL2024001452A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
TW110143066A TWI891942B (zh) 2020-12-01 2021-11-18 氘化化合物
PCT/EP2021/082227 WO2022117359A1 (fr) 2020-12-01 2021-11-18 Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
GBGB2119021.0A GB202119021D0 (en) 2021-11-18 2021-12-24 Injectable and inhalable formulations
US202217574424A 2022-01-12 2022-01-12
EP2022055324 2022-03-02

Publications (1)

Publication Number Publication Date
CL2024001452A1 true CL2024001452A1 (es) 2024-09-27

Family

ID=84440034

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001452A CL2024001452A1 (es) 2021-11-18 2024-05-15 Formulaciones inyectables e inhalables

Country Status (11)

Country Link
EP (1) EP4433049A1 (fr)
JP (1) JP2024540527A (fr)
KR (1) KR20240110836A (fr)
AU (1) AU2022393234A1 (fr)
CA (1) CA3238583A1 (fr)
CL (1) CL2024001452A1 (fr)
CO (1) CO2024007518A2 (fr)
IL (1) IL312859A (fr)
MX (1) MX2024005955A (fr)
WO (1) WO2023089132A1 (fr)
ZA (1) ZA202403906B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007310949A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
ES2984438T3 (es) * 2019-02-22 2024-10-29 Gh Res Ireland Limited 5-metoxi-N,N-dimetiltriptamina (5-meo-dmt) para el tratamiento de la depresión mayor
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3873883B1 (fr) 2019-11-07 2022-12-21 Small Pharma Ltd Procédé de synthèse
EP3902541B1 (fr) 2020-06-02 2022-09-14 Small Pharma Ltd Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés
CN115701994B (zh) * 2020-08-28 2024-03-08 赛本英国有限公司 可注射制剂
IL303288A (en) * 2020-12-01 2023-07-01 Small Pharma Ltd N,N-Dimethyltryptamine compounds partially or fully deuterated

Also Published As

Publication number Publication date
MX2024005955A (es) 2024-06-11
ZA202403906B (en) 2025-08-27
KR20240110836A (ko) 2024-07-16
CA3238583A1 (fr) 2023-05-25
JP2024540527A (ja) 2024-10-31
IL312859A (en) 2024-07-01
WO2023089132A1 (fr) 2023-05-25
EP4433049A1 (fr) 2024-09-25
AU2022393234A1 (en) 2024-06-06
CO2024007518A2 (es) 2024-07-29

Similar Documents

Publication Publication Date Title
ES2708756T3 (es) Materiales y métodos para mejorar la función pulmonar y para la prevención y/o el tratamiento de complicaciones pulmonares inducidas por radiación
ES2897453T3 (es) Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
ES2381664T3 (es) Combinaciones de antagonistas del receptor metabotrópico de glutamato y su uso en el tratamiento de trastornos adictivos
ES2281439T3 (es) Uso de anticonvulsionantes a base de aminoacidos para tratar el dolor.
ES2705698T3 (es) Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib
MX2021005969A (es) Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2017533276A (ja) 認知低下を処置するための方法
CO2024007518A2 (es) Formulaciones inyectables e inhalables
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
ES2984490T3 (es) Composición que comprende nicotina para el tratamiento de hemorragias de la mucosa nasal o paranasal
ES2749053T3 (es) Polimixinas de baja sustitución y sus composiciones
ES2276818T3 (es) Agente que contiene n-clorotaurina, asi como su uso para el tratamiento de polipos de la mucosa.
ES2952367T3 (es) Conjugados terapéuticos basados en PAR-1 y usos de los mismos
US20210015934A1 (en) Method of Treating Parkinson's Disease
JP2016504361A5 (fr)
US20180235940A1 (en) Treatment and management of augmentation in restless legs syndrome
Natalini et al. Analgesic and cardiopulmonary effects of epidural romifidine and morphine combination in horses
Afzal et al. Bioengineered exosomes: Cellular membrane-camouflaged biomimetic nanocarriers for Parkinson’s disease management
Dongfang et al. Preventive and therapeutic effect of sodium rutin (NaR) for comorbid depressive symptoms in chronic pain
RU2622980C1 (ru) Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения
KR102494794B1 (ko) 여성 성기능장애의 치료를 위한 약학 조성물 및 방법